Performing rebiopsies for primary lung cancer and/or their metastases is becoming more and more prominent in daily practice, as the therapeutical spectrum increases and some newer strategies are dependent on immunohistochemical and/or molecular factors. In general, nearly all recurrent lesions or metastases can be reached. However, frequently invasive procedures are necessary with the need to carefully weigh risks and benefits of rebiopsies for the patient in each case. In this review indications for recurrent and progressive disease as well as risks are discussed and alternatives to rebiopsies are shown. This work is the joint opinion from both the endoscopic and thoracic oncology sections of the German Society of Pneumology (DGP).
- Bruckl, W. M.
- Ficker, J. H.
- Tiemann, M.
- Schumann, C.
- Reinmuth, N.
- Heigener, D.
- Schutte, W.
- Eberhardt, R.
- Darwiche, K.
- Wagner, M.
